NRx Pharmaceuticals Completes Ketamine Production Validation
The company has finished commercial-scale manufacturing and stability testing for its new injectable ketamine formulation.
Updated on Oct. 26, 2026 in Substance Abuse
Live Poll
Do you support prioritizing accelerated approvals for generic drugs to combat national hospital supply shortages?
NRx Pharmaceuticals has successfully completed three commercial-scale validation batches of injectable ketamine. This manufacturing milestone follows two years of stability testing that confirms the drug's integrity remains intact at room temperature.
Why it matters
The company aims to address persistent hospital drug shortages by securing FDA approval for its preservative-free injectable ketamine. Successfully meeting manufacturing standards is a critical step in the ongoing generic drug application process.
The drug formulation has successfully maintained purity, potency, and sterility for 2 years of real-time stability testing. Three commercial-scale batches were produced to meet FDA current Good Manufacturing Practice standards.
The players
NRx Pharmaceuticals
A biopharmaceutical company headquartered in Wilmington, Delaware, that focuses on developing treatments for central nervous system disorders.
Nephron Pharmaceuticals
A West Columbia, South Carolina-based manufacturer that partners with organizations to produce specialized sterile medications.
The details
The production process was carried out in partnership with Nephron Pharmaceuticals and utilizes a method that removes the necessity for preservatives. The company now holds commercially releasable inventory as it awaits a final regulatory decision.
Timeline
Two years of real-time stability data were collected between 2024 and 2026.
The FDA regulatory goal date for the drug application review is November 10, 2026.
Health Landscape
This development aligns with the strict requirements of the FDA current Good Manufacturing Practice standards, which govern quality control across the pharmaceutical industry. Adherence to these protocols is essential for firms seeking to transition from experimental stages to national drug distribution.
If approved, this new source of injectable ketamine could help stabilize supply chains for hospitals and clinics facing ongoing drug shortages. Patients needing these medications may see improved availability once the product reaches the market.
The takeaway
Reliable manufacturing processes are essential for ensuring that critical drugs remain potent and safe for hospital use. This update highlights the technical hurdles pharmaceutical companies must clear before their products can reach clinical settings.
What happens next
The FDA is scheduled to reach a regulatory goal date for the drug application on November 10, 2026.
Further reading
Learn more about efforts to address substance use treatments and clinical standards on the Substance Abuse section page.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you support prioritizing accelerated approvals for generic drugs to combat national hospital supply shortages?
